Vulnerability in tumor cells could provide a new therapeutic target
18 november 2026
Researchers have discovered that many tumor cells share the same vulnerability. During cell division, this vulnerability becomes exposed. This discovery provides opportunities for further research into drugs that could target tumor cells through this weak spot.
Like healthy cells, tumor cells also divide. During each cell division, one cell gives rise to two new cells. Throughout this process, the DNA of the original cell is duplicated so that it is also present in the new cell. The transferred DNA ensures that the cell functions properly. In healthy cells, this process is controlled and stable. In tumor cells, however, it is much less controlled, and errors occur more frequently.
Researchers at the Princess Máxima Center found that tumor cells that frequently make errors during cell division are highly dependent on the so-called SKA complex (spindle and kinetochore-associated complex). When researchers switched off this complex in tumor cells in the laboratory, the cells either stopped dividing or divided much more slowly, eventually leading to cell death.
Maud Schoot Uiterkamp is a PhD candidate at the Princess Máxima Center and conducted the research under the supervision of associate research group leader Dr. Gerben Vader. She explains: ‘What makes this discovery particularly remarkable is that we found evidence that the SKA complex is required for cell division in many cancer cells. Healthy cells appear less dependent on this complex. This makes it interesting to investigate whether this dependency is also present in different types of childhood cancer in which cell division errors frequently occur, including germ cell tumors, neuroblastoma and bone cancer.’
‘Although this has only been demonstrated in the laboratory so far, it is very interesting to further investigate the SKA-complex in follow-up studies,’ says Vader. ‘We hope to start that work soon. We want to explore whether this could serve as a starting point for the development of a new drug .’
The study, published today in Nature Communications, was conducted at Amsterdam UMC’s Cancer Center Amsterdam and the Princess Máxima Center. This research was partly made possible through financial support from Oncode Institute (via the Medema group), KWF and Amsterdam UMC.
For professionals
The research into the spindle and kinetochore–associated (SKA) complex builds on earlier research that identified kinesin KIF18A as a therapeutic target for cancers characterized by chromosomal instability. A drug targeting KIF18A is currently being investigated in clinical studies.
Using abnormal chromosome numbers and chromosomal instability as a starting point, the researchers found that these chromosomally unstable tumor cells depend on the SKA complex for proper cell division. As with KIF18A, this dependency appears to be specific to these tumor cells.
Schoot Uiterkamp: ‘We observed that the SKA complex is epistatic to KIF18A, suggesting that these proteins have similar effects and that we are dealing with a comparable vulnerability in the cellular mechanisms of the tumor cell. We therefore hope that this discovery will be followed by further research into new therapeutic applications for both children and adults.’